Certification: On third-party certification, the site doesn't say. Where it ships: The site doesn't say which states it serves. Last checked: July 2026, against MEDVidi's own pages. Published price: MEDVidi publishes no price we could read; the figure comes after the intake. What it sells: Brand-name medication as well as compounded, injectable route only. Licensing & trust: 68/100 on the scored dimension of that name — one of the six in our published methodology. Checks out on everything except cost: MEDVidi publishes no monthly figure, so what you will pay is only knowable after the intake.

C52/100

Desk Score

Ranked #470

MEDVidi

Q: What does MEDVidi cost?

Semaglutide: Not listed on MEDVidi's site (checked July 2026). Tirzepatide: Not listed on MEDVidi's site (checked July 2026). There is no published figure to compare: MEDVidi does not put a price on the pages we read, so the cost is only knowable once the intake is finished. All figures as published on MEDVidi's own site and read in July 2026. Prices change — confirm before you order.

MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide).

Desk Score 52/100 (C) · Verified July 2026

Visit MEDVidi ↗Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way.

Is MEDVidi legit?

Only what MEDVidi publishes and what we could check ourselves — nothing inferred. See the methodology.

Certification: On third-party certification, the site doesn't say.
Where it ships: The site doesn't say which states it serves.
Last checked: July 2026, against MEDVidi's own pages.
Published price: MEDVidi publishes no price we could read; the figure comes after the intake.
What it sells: Brand-name medication as well as compounded, injectable route only.
Licensing & trust: 68/100 on the scored dimension of that name — one of the six in our published methodology.

Checks out on everything except cost: MEDVidi publishes no monthly figure, so what you will pay is only knowable after the intake.

What does MEDVidi cost?

Each figure exactly as MEDVidi publishes it, with the condition attached to it spelled out.

Semaglutide

Not listed on MEDVidi's site (checked July 2026)

Tirzepatide

Not listed on MEDVidi's site (checked July 2026)

There is no published figure to compare: MEDVidi does not put a price on the pages we read, so the cost is only knowable once the intake is finished.

All figures as published on MEDVidi's own site and read in July 2026. Prices change — confirm before you order.

Semaglutide: Not listed on MEDVidi's site (checked July 2026)
Tirzepatide: Not listed on MEDVidi's site (checked July 2026)
Coverage: Not listed on MEDVidi's site (checked July 2026)
Brand-name: Yes

Line MEDVidi up against its closest alternatives. Or go one-on-one: MEDVidi vs CoreAge Rx.

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency30/100

State access24/100

Molecule range79/100

Onboarding speed66/100

Support responsiveness70/100

Licensing & trust68/100

What we like

Licensed providers can prescribe brand-name Zepbound and Wegovy
Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
Prescriptions sent to the patient's pharmacy of choice, so insurance can be used

Where points come off

Consult-fee model: medication is not included and its cost is separate
No medication pricing is published
State list is shown as a map rather than enumerated

The bottom line — C

Best for: People who want a licensed provider to prescribe brand glp-1 they fill with insurance.

MEDVidi ranks #470 of 542 providers scored — see #1, CoreAge Rx here.

Visit MEDVidi ↗

Pricing and verification reflect MEDVidi's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on MEDVidi's site. Not medical advice; see our disclosure.

← Back to the ranking